GOSS Stock Forecast & Price Target

Gossamer Bio is viewed favorably because seralutinib shows a biologically meaningful effect in PAH, with a 13-meter placebo-adjusted 6MWD benefit globally and roughly 27–28 meters in North America and Western Europe, while subgroup and TORREY data strengthen the case that the drug can address patients still underserved by current therapy. Management’s guidance that the FDA treated PROSERA as a review issue rather than a filing issue supports the regulatory path, and NDA acceptance would unlock a $125 million tranche from the $250 million September PIPE, lifting committed proceeds to $150 million by year-end. The investment case is further reinforced by a potentially broad, additive commercial role alongside existing treatments, manageable safety concerns, and an expanding PAH plus PH-ILD opportunity that could support long-term growth.

Gossamer Bio is a high-risk, clinical-stage company whose valuation is heavily dependent on seralutinib, yet PROSERA failed to meet its prespecified primary endpoint and the FDA may view the data as insufficient for approval or may require a narrower label or another controlled study. Even where efficacy appears more compelling in intermediate/high-risk and CTD-PAH subsets, the +13.3 m placebo-adjusted 6MWD gain in the ITT population is modest, and discontinuations were materially higher with seralutinib than placebo (15.0% versus 5.8%), raising concerns about tolerability and chronic persistence. Commercially, PAH is already crowded with established therapies, and after Chiesi’s exit Gossamer must fund development and launch itself, increasing dilution risk and execution pressure.